Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Medical Oncology
•
Leukemia
•
MD Anderson
•
AML
•
AYA
•
AYA Tumor Board
If AYA patients with AML are MRD negative after 1 cycle of chemotherapy, and high risk for relapse, should they receive additional cycles of chemotherapy or proceed directly to transplant?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
How do you choose between the different available CAR-T cell therapy products for the treatment of relapsed Ph-negative ALL?
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?
How do you manage ocular hemorrhages while on acalabrutinib for CLL?
